Advanced search
Publication Cover
International Journal of General Medicine Volume 14, 2021 - Issue
Submit an article Journal homepage
189
Views
7
CrossRef citations to date
0
Altmetric
Original Research

Identification of a Vulnerable Group for Post-Acute Sequelae of SARS-CoV-2 (PASC): People with Autoimmune Diseases Recover More Slowly from COVID-19

Nancy Dreyer1 Real World Solutions, IQVIA Cambridge, Cambridge, MA, USACorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0003-0153-8286View further author information
ORCID Icon,
Natalia Petruski-Ivleva1 Real World Solutions, IQVIA Cambridge, Cambridge, MA, USAView further author information
,
Lisa Albert1 Real World Solutions, IQVIA Cambridge, Cambridge, MA, USAView further author information
,
Damir Mohamed2 Real World Solutions, IQVIA Courbevoie, Courbevoie, FranceView further author information
,
Emma Brinkley1 Real World Solutions, IQVIA Cambridge, Cambridge, MA, USAView further author information
,
Matthew Reynolds1 Real World Solutions, IQVIA Cambridge, Cambridge, MA, USAView further author information
&
Stephen Toovey3 Pegasus Research, Bottmingen, SwitzerlandView further author information
 show all
Pages 3941-3949 | Published online: 26 Jul 2021

References

  • Yelin D, Margalit I, Yahav D, Runold M, Bruchfeld J. Long COVID-19-it’s not over until? Clin Microbiol Infect. 2020;S1198-743X(20)30750-3.
  • Baang JH, Smith C, Mirabelli C, et al. Prolonged severe acute respiratory syndrome coronavirus 2 replication in an immunocompromised patient. J Infect Dis. 2021;223(1):23–27. doi:10.1093/infdis/jiaa666
  • Liu Y, Sawalha AH, Lu Q. COVID-19 and autoimmune diseases. Curr Opin Rheumatol. 2021;33(2):155–162. doi:10.1097/BOR.0000000000000776
  • Dreyer NA, Reynolds M, Mack CD, et al. Self-reported symptoms from exposure to COVID-19 provide support to clinical diagnosis, triage and prognosis: an exploratory analysis. Travel Med Infect Dis. 2020;38:101909. doi:10.1016/j.tmaid.2020.101909
  • U.S. Department of Health and Human Services, Food and Drug Administration. Assessing COVID-19-related symptoms in outpatient adults and adolescent subjects in clinical trials of drugs and biological products for COVID-19 treatment and prevention. Guidance for industry; September 2020. Available from: https://www.fda.gov/media/142143/download. Accessed March 23, 2021.
  • Huang C, Huang L, Wang Y, et al. Six-month consequences of COVID-19 in patients discharged from hospital: a Cohort Study. Lancet. 2021;397(10270):220–232. doi:10.1016/S0140-6736(20)32656-8
  • El Sayed S, Shokry D, Gomaa SM. Post-COVID-19 fatigue and anhedonia: a Cross-Sectional Study and their correlation to post-recovery period. Neuropsychopharmacol Rep. 2021;41(1):50–55. doi:10.1002/npr2.12154
  • Venkatesan P. NICE guideline on long COVID. Lancet Respir Med. 2021;9(2):129. doi:10.1016/S2213-2600(21)00031-X
  • van der Sar-van der Brugge S, Talman S, Boonman-de Winter L, et al. Pulmonary function and health-related quality of life after COVID-19 pneumonia. Respir Med. 2021;176:106272. doi:10.1016/j.rmed.2020.106272
  • Cortés-Telles A, López-Romero S, Figueroa-Hurtado E, et al. Pulmonary function and functional capacity in COVID-19 survivors with persistent dyspnea. Respir Physiol Neurobiol. 2021;288:103644. doi:10.1016/j.resp.2021.103644
  • Rashedi J, Mahdavi Poor B, Asgharzadeh V, et al. Risk factors for COVID-19. Infez Med. 2020;28(4):469–474.
  • Sudre CH, Murray B, Varsavsky T, et al. Attributes and predictors of long COVID. Nat Med. 2021;27(4):626–631. doi:10.1038/s41591-021-01292-y
  • Dreyer NA, Blackburn SCF, Mt-Isa S, et al. Direct-to-patient research: piloting a new approach to understanding drug safety during pregnancy. JMIR Public Health Surveill. 2015;1(2):e22. doi:10.2196/publichealth.4939
  • Fung M, Babik JM. COVID-19 in immunocompromised hosts: what we know so far. Clin Infect Dis. 2020;72:ciaa863.
  • Dai M, Liu D, Liu M, et al. Patients with cancer appear more vulnerable to SARS-CoV-2: a Multicenter Study during the COVID-19 outbreak. Cancer Discov. 2020;10(6):783–791. doi:10.1158/2159-8290.CD-20-0422
  • Kuderer NM, Choueiri TK, Shah DP, et al. Clinical impact of COVID-19 on patients with cancer (CCC19): a Cohort Study [published correction appears in Lancet. 2020 Sep 12;396(10253):758]. Lancet. 2020;395(10241):1907–1918. doi:10.1016/S0140-6736(20)31187-9
  • Montero F, Martínez-Barrio J, Serrano-Benavente B, et al. Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes. Rheumatol Int. 2020;40(10):1593–1598. doi:10.1007/s00296-020-04676-4
  • Scoppettuolo P, Borrelli S, Naeije G. Neurological involvement in SARS-CoV-2 infection: a clinical systematic review. Brain Behav Immun Health. 2020;5:100094. doi:10.1016/j.bbih.2020.100094
  • Blumentals WA, Arreglado A, Napalkov P, Toovey S. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a Retrospective Cohort Study. BMC Musculoskelet Disord. 2012;27(13):158. doi:10.1186/1471-2474-13-158
  • Alhazzani W, Evans L, Alshamsi F, et al. Surviving sepsis campaign guidelines on the management of adults with coronavirus disease 2019 (COVID-19) in the ICU: first update. Crit Care Med. 2021;49(3):e219–e234. doi:10.1097/CCM.0000000000004899
  • Snow TAC, Saleem N, Ambler G, Nastouli E, Singer M, Arulkumaran N. Tocilizumab in COVID-19: a meta-analysis, trial sequential analysis, and meta-regression of randomized-controlled trials. Intensive Care Med. 2021;21:1–12.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.